3 chapters across the catalog
Ozempic and Wagovy have become viral sensations for off-label weight loss, despite being designed for type 2 diabetes management. The hosts discuss the pharmaceutical industry's marketing strategies and potential long-term side effects, including pancreatitis and gastrointestinal issues.
Reports suggest that semaglutide drugs like Ozempic may inadvertently cure other addictions, such as alcoholism, vaping, and gambling. This trend has caused concern on Wall Street, with companies like Walmart reporting a decline in snack sales as the drug disrupts traditional consumption patterns.
The hosts compare the current Ozempic craze to the 1990s Fen-Phen scandal, which resulted in massive lawsuits due to heart valve failure. They speculate that Pfizer's failure to produce a competing weight-loss drug may lead to increased regulatory and legal pressure on Novo Nordisk.
